Title:
RECOMBINANT FUSION PROTEIN DERIVED FROM HR REGION OF S2 PROTEIN OF SARS-COV-2 AND APPLICATION OF RECOMBINANT FUSION PROTEIN
Document Type and Number:
WIPO Patent Application WO/2023/051850
Kind Code:
A1
Abstract:
Disclosed are a recombinant fusion protein derived from an HR region of an S2 protein of SARS-CoV-2 and an application of the recombinant fusion protein. The SARS-CoV-2 recombinant fusion protein is a recombinant fusion protein obtained by linking two membrane fusion-related conserved amino acid sequences HR1 and HR2 of the SARS-CoV-2 membrane protein S2 protein by means of a linking peptide. The recombinant fusion protein can be induced and expressed in Escherichia coli, has high expression quantity, and is easy to purify. The SARS-CoV-2 recombinant fusion protein provided by the present invention can form and maintain a stable dimer structure, simulates the conformation of a SARS-CoV-2 membrane fusion intermediate state, can be used as a detection raw material for detecting a SARS-CoV-2 membrane fusion process, has good anti-SARS-CoV-2 activity and good immunogenicity, and has a wide application prospect in the fields of development of drugs for preventing or treating SARS-CoV-2 proteins and development of SARS-CoV-2 vaccines and anti-SARS-CoV-2 antibodies.
More Like This:
Inventors:
PANG WEI (CN)
ZHENG YONGTANG (CN)
HE WENQIANG (CN)
HE XIAOYAN (CN)
LUO RONGHUA (CN)
LU YING (CN)
SHEN FAN (CN)
ZHENG YONGTANG (CN)
HE WENQIANG (CN)
HE XIAOYAN (CN)
LUO RONGHUA (CN)
LU YING (CN)
SHEN FAN (CN)
Application Number:
PCT/CN2022/135269
Publication Date:
April 06, 2023
Filing Date:
November 30, 2022
Export Citation:
Assignee:
KUNMING INST ZOOLOGY CAS (CN)
International Classes:
C07K19/00; C07K16/10; C12N15/70; G01N33/569
Domestic Patent References:
| WO2021155733A1 | 2021-08-12 |
Foreign References:
| CN112409496A | 2021-02-26 | |||
| CN112898437A | 2021-06-04 | |||
| CN111560054A | 2020-08-21 | |||
| CN112538105A | 2021-03-23 | |||
| CN112321688A | 2021-02-05 |
Other References:
NI, LING ET AL.: "Design of recombinant protein-based SARS-CoV entry inhibitors targeting the heptad-repeat regions of the spike protein S2 domain", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 330, no. 1, 29 April 2005 (2005-04-29), XP004801579, ISSN: 0006-291X, DOI: 10.1016/j.bbrc.2005.02.117
LING, RONGSONG ET AL.: "In silico design of antiviral peptides targeting the spike protein of SARS-CoV-2", PEPTIDES, vol. 130, 5 May 2020 (2020-05-05), XP086204019, ISSN: 0196-9781, DOI: 10.1016/j.peptides.2020.170328
LING, RONGSONG ET AL.: "In silico design of antiviral peptides targeting the spike protein of SARS-CoV-2", PEPTIDES, vol. 130, 5 May 2020 (2020-05-05), XP086204019, ISSN: 0196-9781, DOI: 10.1016/j.peptides.2020.170328
Attorney, Agent or Firm:
XU&PARTNERS, LLC. (CN)
Download PDF: